Ono Pharmaceutical Signs a Multi-Year Collaboration with LifeArc and Cancer Research UK to Develop Immuno-Therapies for Cancer

 Ono Pharmaceutical Signs a Multi-Year Collaboration with LifeArc and Cancer Research UK to Develop Immuno-Therapies for Cancer

Ono Pharmaceutical Signs a Multi-Year Collaboration with LifeArc and Cancer Research UK to Develop Immuno-Therapies for Cancer

Shots:

  • Cancer Research and LifeArc to receive upfront, milestones and royalties on sales of products. Ono to get an option to license the developed product with exclusive WW commercialization rights and will take care of its clinical development for identifying new therapeutic targets & target validation
  • LifeArc will utilize its antibody screening and development expertise for antibody projects and Cancer Research UK’s Therapeutic Discovery Labs will take care of small molecule project. In 2017, Cancer Research UK and LifeArc collaborated to develop immunotherapies for cancer
  • Immunotherapies are molecules promoting or suppress immune responses to restore immune homeostasis and cure disease related to autoimmunity, transplantation rejection, and infectious disease

Click here to read full press release/ article | Ref: LifeArc | Image: GMP

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post